2025 年 42 巻 3 号 p. 187-190
DIA (Drug Information Association) was established in 1964 to support the research and development of pharmaceuticals and medical devices. DIA Japan activities started in 1994. Since then, pharmaceutical companies, regulatory authorities, and academia have exchanged information. The author has participated in DIA Japan events since 2015, especially in project management training for medical institutions, statistical workshops, and the Japan Annual Meeting. 2023 and 2024, as a program committee member, the author organized sessions on neurological diseases and post–marketing surveillance. The author also participated in the Patient Engagement community, conducting sessions on the importance of patient and public involvement (PPI). In addition, the author has been a member of the Contents Committee since 2024, proposing and supporting programs. Through DIA activities, the author has been exposed to the latest drug development and hopes that more neurologists will join.
